{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:21:00Z","timestamp":1768004460870,"version":"3.49.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100010909","name":"Young Scientists Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010909","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>A novel approach for treatment of enterovirus infections was characterized. Application of treatment course of consecutive alternating administration (CAA) of triple combination of enterovirus replication inhibitors in experimental infections (20 MLD50) with coxsackievirus B3 (CVB3) strains in newborn mice is presented. It was established that in infection with cardiotropic Woodruff strain the combination of pleconaril, \u041cDL-860 and oxoglaucine (PMO) subjected to the CAA scheme, a significant protective effect was observed. Monotherapeutic courses as well as simultaneously daily applied PMO were without effect. Analogous data were observed at experimental infection with the neurotriopic Nancy strain of CVB3. Following IC50 values of virus samples taken every day from target organs of infected animals during the whole period of study, a drug-resistance was established in monotherapy with compounds-partners in the PMO combination. At courses by the treatment scheme CAA of PMO development of drug-resistance was not established, but an increased susceptibility to the effect of the inhibitor-components in the combination was proven. Toxicity of PMO applied via the CAA scheme and in the monotherapeutic courses in both healthy and CVB3 infected animals was recorded. All data obtained prove the potential of the CAA treatment scheme for development of effective chemotherapy of enterovirus infections.<\/jats:p>","DOI":"10.1093\/femspd\/ftaa065","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T19:16:00Z","timestamp":1602702960000},"source":"Crossref","is-referenced-by-count":6,"title":["Effect of Consecutive Alternating Administration of a Triple Combination of Anti-Enteroviral Compounds in Mice Infected with Coxsackievirus B3"],"prefix":"10.1093","volume":"78","author":[{"given":"Adelina","family":"Stoyanova","sequence":"first","affiliation":[{"name":"The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, 26, Acad. Georgi Bonchev Street, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel S","family":"Galabov","sequence":"additional","affiliation":[{"name":"The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, 26, Acad. Georgi Bonchev Street, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"2020120812432530700_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0168-1656(95)00088-7","article-title":"Modification of translation control elements as a new approach to design of attenuated picornavirus strains","volume":"44","author":"Agol","year":"1966","journal-title":"J Biotechnol"},{"key":"2020120812432530700_bib5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1021\/acsinfecdis.7b00053","article-title":"Allosteric regulation of phosphatidylinositol 4-kinase III beta by an anti-picornavirus compound MDL-860","volume":"3","author":"Arita","year":"2017","journal-title":"ACS Infect Dis"},{"key":"2020120812432530700_bib4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/1348-0421.12261","article-title":"Phosphatidylinositol 4-kinase III beta is the target of oxoglaucine and pachydipol (Ro 09\u20130179) for their anti-poliovirus activity, and locates at upstream of the target step of brefeldin A in poliovirus replication","volume":"59","author":"Arita","year":"2015","journal-title":"Microbiol Immunol"},{"key":"2020120812432530700_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acsinfecdis.5b00122","article-title":"Mechanism of poliovirus resistance to host phosphatidylinositol-4 kinase III \u03b2 inhibitor","volume":"2","author":"Arita","year":"2016","journal-title":"ACS Infect Dis"},{"key":"2020120812432530700_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/1348-0421.12144","article-title":"Phosphatidylinositol-4 kinase III beta and oxysterol-binding protein accumulate unesterified cholesterol on poliovirus-induced membrane structure","volume":"58","author":"Arita","year":"2014","journal-title":"Microbiol Immunol"},{"key":"2020120812432530700_bib6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/095632029700800502","article-title":"Antipicornavirus drugs: current status","volume":"8","author":"Diana","year":"1997","journal-title":"Antivir Chem Chemother"},{"key":"2020120812432530700_bib7","first-page":"3","article-title":"Coxsackie viruses and quasi species theory: evolution of enteroviruses","volume":"323","author":"Domingo","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"2020120812432530700_bib8","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China","volume":"370","author":"Fengcai","year":"2014","journal-title":"N Engl J Med"},{"key":"2020120812432530700_bib9","first-page":"47","article-title":"Perspectives for effective chemotherapy of enterovirus infections","volume-title":"New Trends of Microbiology (65th Anniversary of the Stephan Angeloff Institute of Microbiology)","author":"Galabov","year":"2012"},{"key":"2020120812432530700_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4172\/jaa.1000e138","article-title":"Consecutive alternating administration of antiviral combinations: a novel treatment approach against coxsackievirus B1 neuroinfection","volume":"8","author":"Galabov","year":"2016","journal-title":"J Antivir Antiretrovir"},{"key":"2020120812432530700_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040206620906061","article-title":"Genome analysis of coxsackievirus B1 isolates during the consecutive alternating administration course of triple antiviral combination in newborn mice","volume":"28","author":"Grozdanov","year":"2020","journal-title":"Antivir Chem Chemother"},{"key":"2020120812432530700_bib12","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1128\/AAC.43.3.634","article-title":"Single-dose pharmacokinetics of a pleconaril oral solution in children and adolescents","volume":"43","author":"Kearns","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2020120812432530700_bib13","first-page":"3","article-title":"Epidemiology","volume-title":"Human Enterovirus Infections","author":"Morens","year":"1995"},{"key":"2020120812432530700_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mossman","year":"1983","journal-title":"J Immunol Methods"},{"key":"2020120812432530700_bib15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-59745-569-5_21","article-title":"A new highly potent antienteroviral compound","volume-title":"National Institute of Allergy and Infectious Diseases, NIH, Frontiers in Research","author":"Nikolaeva-Glomb","year":"2008"},{"key":"2020120812432530700_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/jmv.10570","article-title":"Inhibition of coxsackie B3 virus induced myocarditis in mice by 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile","volume":"72","author":"Padalko","year":"2004","journal-title":"J Med Virol"},{"key":"2020120812432530700_bib17","first-page":"839","article-title":"Enteroviruses: polioviruses, coxsackieviruses, echoviruses and newer enteroviruses","author":"Pallansch","year":"2005"},{"key":"2020120812432530700_bib18","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/AAC.43.9.2109","article-title":"Activity of pleconaril against enteroviruses","volume":"43","author":"Pevear","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2020120812432530700_bib19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1128\/AAC.22.4.639","article-title":"Activity of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860) against picornaviruses in vitro","volume":"22","author":"Powers","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"2020120812432530700_bib20","first-page":"493","article-title":"A simple method of estimating 50% endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Amer J Hygiene"},{"key":"2020120812432530700_bib21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.chom.2014.10.003","article-title":"Rhinovirus uses a phosphatidylinositol 4-phosphate\/cholesterol counter-current for the formation of replication compartments at the ER-Golgi interface","volume":"16","author":"Roulin","year":"2014","journal-title":"Cell Host Microbe"},{"key":"2020120812432530700_bib22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dki263","article-title":"Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment","volume":"56","author":"Schmidtke","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2020120812432530700_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2008.09.002","article-title":"New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3","volume":"81","author":"Schmidtke","year":"2009","journal-title":"Antivir Res"},{"key":"2020120812432530700_bib24","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1099\/0022-1317-68-11-2729","article-title":"The mutation rate and variability of eukaryotic viruses: an analytical review","volume":"68","author":"Smith","year":"1987","journal-title":"J Gen Virol"},{"key":"2020120812432530700_bib25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.antiviral.2015.07.004","article-title":"Effect of consecutive alternating administration (CAA) of a triple anti-enteroviral combination on coxsackievirus B1 neuroinfection in mice","volume":"21","author":"Stoyanova","year":"2015","journal-title":"Antivir Res"},{"key":"2020120812432530700_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/2040206616671571","article-title":"Anti-enterovirus triple combination of viral replication inhibitors: activity against coxsackievirus B1 neuroinfection in mice","volume":"24","author":"Stoyanova","year":"2015","journal-title":"Antivir Chem Chemother"},{"key":"2020120812432530700_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1128\/AAC.22.4.635","article-title":"Antiviral activity and mechanism of action of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitril (MDL-860)","volume":"22","author":"Torney","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"2020120812432530700_bib28","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.antiviral.2009.11.003","article-title":"Avoiding drug-resistance development by novel approach of combining enteroviral substances against coxsackievirus B1 infection in mice","volume":"85","author":"Vassileva-Pencheva","year":"2010","journal-title":"Antivir Res"},{"key":"2020120812432530700_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2334-3-30","article-title":"An improved microtiter assay for evaluating anti-HIV-1 neutralizing antibodies from sera or plasma","volume":"3","author":"Zhang","year":"2003","journal-title":"BMC Infec Dis"}],"container-title":["Pathogens and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/femspd\/advance-article-pdf\/doi\/10.1093\/femspd\/ftaa065\/33983132\/ftaa065.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/femspd\/article-pdf\/78\/9\/ftaa065\/34805714\/ftaa065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/femspd\/article-pdf\/78\/9\/ftaa065\/34805714\/ftaa065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T23:08:57Z","timestamp":1607555337000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/femspd\/article\/doi\/10.1093\/femspd\/ftaa065\/5935069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,11,23]]}},"URL":"https:\/\/doi.org\/10.1093\/femspd\/ftaa065","relation":{},"ISSN":["2049-632X"],"issn-type":[{"value":"2049-632X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,10,22]]},"article-number":"ftaa065"}}